Latigo Biotherapeutics, Inc. 424B4final IPO prospectus

Executive Summary

Latigo Biotherapeutics develops non-opioid pain medicines, with oral Nav1.8 inhibitors targeting acute pain and chronic musculoskeletal pain; it has no revenue or approved products. FY2025 net loss widened 78.4% to $(109)M as lead-program development accelerated, while encouraging acute-pain results remain unconfirmed across pain models. Its $346M, entirely primary IPO at $18.00 implies a $1.14B market capitalization and gives IPO buyers 30.4% of outstanding shares before option dilution. Investors are funding clinical and regulatory milestones—not an established earnings stream—with pivotal acute-pain and chronic-pain proof-of-concept results expected in H2 2027 and further financing required beyond the offering.

The Offering

• Size and implied valuation: 19.2M shares × $18.00 = $346M gross; 63.2M post-offering shares imply $1.14B market capitalization and a 30.4% buyer stake. Including 9.85M outstanding options, 0.240M subsequent grants and 0.533M IPO option grants gives a fully diluted count of 73.9M shares, $1.33B capitalization and a 26.0% buyer stake, before exercise proceeds or future awards. Revenue and earnings multiples are not meaningful for this pre-revenue, loss-making company.
• Terms and distribution: all shares are company-issued, with no secondary sales; expected net proceeds are ≈$316M, or ≈$364M with full exercise of the 30-day, 2.88M-share option. Goldman Sachs, Jefferies, Leerink Partners and Guggenheim Securities underwrite the Nasdaq Global Select Market listing, LTGO.
• Proceeds: the company receives the funds, rather than selling holders or lenders. Together with existing cash, ≈$125M is allocated to LTG-001 through Phase 3 results, regulatory submission and commercial readiness; ≈$46.2M to LTG-321 through Phase 2 results and Phase 3 initiation; the balance supports other R&D and working capital.
• Dilution: each $18.00 share is backed by $6.11 of net tangible assets after the IPO—a $11.89 gap. Existing holders’ disclosed average purchase price was $7.30; asset backing is predominantly financing cash, not commercial operating assets.
• Capitalization bridge: before the IPO, cash was $42.2M and equity $(253)M. June notes supplied $34.8M net; preferred stock and $35.0M note principal plus interest convert into common shares, producing $77.0M cash and $70.8M equity before offering proceeds. After the IPO—assuming these transactions and the base offering—cash reaches $393M and equity $386M; preferred conversion itself adds no cash.
• Timing and directed shares: pricing/prospectus date 8/6/2026; delivery expected on or about 8/10/2026. Up to 3.0% of shares are reserved at the IPO price under the directed share program; participating directors and officers remain subject to lock-ups.
• Resale overhang: substantially all 44.0M non-offering shares are covered by 180-day lock-ups ending 2/2/2027, subject to exceptions and early release. Holders of 43.1M shares have registration rights, making potential future supply substantially larger than the initial offering.

Key Financial Highlights

Amounts in $M; historical figures unless labeled otherwise. Annual statements are audited; interim statements are unaudited.

• Spending mechanism: FY2025 LTG-001 costs rose by $35.4M, largely clinical trials and manufacturing. Q1 2026 R&D eased as manufacturing and terminated-program spending declined, but administrative expense more than doubled as staffing and public-company preparation expanded.
• Cash versus loss: FY2025 operating cash use was below net loss partly because of $6.73M stock-based compensation and other non-cash charges; Q1 2026 cash use exceeded loss as working-capital outflows outweighed non-cash adjustments.
• Negative equity: $289M of convertible preferred stock sat outside stockholders’ equity, while accumulated losses reached $266M. The deficit is not equivalent to borrowing: March liabilities totaled $14.6M, and the $35.0M notes were issued later and convert at closing.
• Runway: preliminary cash was ≈$54.8M at 6/30/2026. Management projects funding through year-end 2028 after the IPO, but explicitly expects additional capital needs to complete development and commercialization.

Business Model and Growth Drivers

• Commercial model: future medicine sales depend on approval and reimbursement. Management seeks differentiation through rapid relief, opioid sparing and tolerability; Vertex’s approved Journavx validates Nav1.8 but establishes a competitive benchmark.
• LTG-001 evidence: in 343 abdominoplasty patients, high-dose treatment improved cumulative pain relief over 48 hours by 62.1 points versus placebo, against the opioid comparator’s 40.9-point placebo-adjusted improvement. Relief began at 52 minutes vs 83 minutes with the comparator; 52.3% remained opioid-free vs 22.1% on placebo. These results suggest differentiation, not established superiority.
• Development sequence: Phase 3 bunionectomy and ≈400-patient safety trials are planned for H2 2026, with results in H2 2027. The abdominoplasty trial may serve as one pivotal study, subject to regulatory requirements.
• Pipeline expansion: LTG-321’s ≈120-patient knee-osteoarthritis Phase 2 trial targets H2 2027 results; laboratory pain-tolerance activity lasting 24 hours supports once-daily development but does not establish chronic-pain efficacy. LTG-418 and intravenous LTG-001 offer earlier-stage formulation opportunities.

Governance and Control

• Voting influence: one common share carries one vote. Post-IPO holdings include Westlake 20.9%, Foresite 14.3%, 5AM 11.6% and Blue Owl 5.0%; director-affiliated funds retain substantial influence without dual-class voting.
• Entrenchment: staggered board terms, director removal requiring cause and 66⅔% approval, and restrictions on stockholder actions can impede takeover premiums or leadership changes.
• Financing and incentives: director-affiliated investors supplied ≈$75.0M of the FY2025 preferred financing. Equity compensation creates continuing dilution: the new plan includes recycled awards, and annual reserve increases can reach 5.0%, plus up to 1.0% under the employee purchase plan.

Risk Assessment

• Audit and funding: the auditor flagged going-concern doubt, and unreviewed journal entries and reconciliations created a material control weakness; IPO liquidity addresses near-term funding, not ultimate development costs or remediation.
• Acute-pain validation: a dental-pain trial failed to separate significantly from placebo, and a prior clinical hold lasted from 5/2024 through 11/2024; bunionectomy efficacy or broader safety failures could undermine the lead asset.
• Chronic-pain translation: LTG-321’s laboratory signal may not translate to sustained osteoarthritis relief, limiting pipeline diversification.
• Adoption and reimbursement: inexpensive alternatives and payer restrictions around Journavx’s ≈$31.00 daily price could constrain pricing despite clinical benefits.
• Outsourced supply: no manufacturing facilities or long-term supply commitments, plus Indian and Chinese sourcing exposure, create trial and commercial disruption risk.
• Licensed rights: LTG-001 depends on the Lieber Institute license; termination or inadequate patent protection could impair its economics or development.
• Valuation and dilution: $1.14B values unapproved programs rather than sales; clinical setbacks, further financing and the 2/2/2027 lock-up expiry could materially reset expectations.

Investor Actionables

At $18.00, the case requires reproducible acute-pain differentiation and credible chronic-pain efficacy. Proceeds buy the next clinical and regulatory milestones, not a fully funded commercial launch.

• Lead-asset validation: track the company’s H2 2027 Phase 3 results against its positive 343-patient study; consistent efficacy and broader safety support the case, while another failed pain model weakens it.
• Chronic-pain evidence: assess the ≈120-patient LTG-321 trial’s osteoarthritis pain endpoint; meaningful benefit supports a second franchise, while failure leaves value concentrated in LTG-001.
• Funding execution: test the year-end 2028 runway against program spending and stated allocations; timely milestones without premature fundraising support management’s assumptions, while delays and escalating cash use challenge them.
• Share supply: around 2/2/2027, monitor registered sales and award issuance; substantial insider selling or dilution would increase the clinical success needed to sustain per-share value.